Xenon Pharmaceuticals Inc. announced that it has entered into a share purchase agreement for a private placement of 275,337 common shares at a price of $19.9755 per share for gross proceeds of approximately $5,499,994 on September 8, 2021. The transaction will include participation from Neurocrine Biosciences, Inc. The purchase price represents a 15% premium to the company's 30-day volume-weighted average price immediately prior to the public announcement of the clinical trial application approval. The shares are subject to lock-up restriction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.75 USD | +1.74% | +8.02% | -5.02% |
19/04 | Xenon Pharmaceuticals Inc. Announces Board Resignations | CI |
11/03 | Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.02% | 3.3B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Inc. announced that it expects to receive $5.499994 million in funding from Neurocrine Biosciences, Inc.